AstraZeneca said on March 24 the company’s drug Imfinzi, along with chemoradiotherapy, failed to achieve the main goal of improving survival in patients with locally advanced cervical cancer without the disease worsening.
Global immunology firm Argenx shared positive topline results from the company’s ongoing study on the use of efgartigimod for generalized myasthenia gravis (gMG).
AstraZeneca said on March 21 the company’s antibody-based cocktail to prevent and treat COVID-19 retained neutralizing activity against Omicron coronavirus variants, including the highly contagious BA.2 sub-variant, in an independent lab study.
The U.S. government will run out of supplies of COVID-19 treatments known as monoclonal antibodies as soon as late May and will have to scale back plans to get more unless Congress provides more funding, the White House said on March 15.
An experimental oral drug being developed by Redhill Biopharma Inc. interrupts a process that helps the coronavirus infect cells and might keep COVID-19 patients from becoming seriously ill, the company said. Additionally, the risk of hospitalization after vaccination with Johnson & Johnson’s COVID-19 vaccine was about five times higher than for those who received the Pfizer and BioNTech shot, a large French study found.
The U.S. Food and Drug Administration revised the emergency use authorization (EUA) for AstraZeneca’s Evusheld to a higher dose to be effective in the prevention of COVID-19.
Antibodies induced by mRNA COVID-19 vaccines keep improving in quality for at least six months while the immune system continues to “train” its antibody-producing B cells, according to a new study. In other research, dysfunctional red blood cells contribute to the blood vessel injuries common in severe COVID-19, according to laboratory studies that also may suggest a way to treat the problem.
The World Health Organization indicated WHO is tracking four Omicron subvariants: BA.1, BA.1.1, BA.2 and BA.3. BA.2 has a growth advantage over BA.1, the variant responsible for the recent Omicron surge.
The U.S. Food and Drug Administration sent Denali Therapeutics a formal clinical hold letter regarding the investigational new drug (IND) application for the company’s Alzheimer’s drug candidate DNL919.
Eli Lilly and Co. entered an agreement with the U.S. government to supply up to 600,000 doses of the company’s developmental COVID-19 antibody drug for at least $720 million.
